This targeted strategy not only addresses the chemoresistance challenge in NPC but also heralds a promising avenue for improving patient outcomes, underscoring BMI1 as an innovative therapeutic target in the fight against drug resistance in cancer treatment. This evidence concerns the gene BMI1 and cancer.